DESCRIPTION: Antimicrobial overuse is a major health care issue that contributes to antibiotic resistance. Such overuse includes unnecessarily long durations of antibiotic therapy in patients with common bacterial infections, such as acute bronchitis with chronic obstructive pulmonary disease (COPD) exacerbation, community-acquired pneumonia (CAP), urinary tract infections (UTIs), and cellulitis. This article describes best practices for prescribing appropriate and short-duration antibiotic therapy for patients presenting with these infections. METHODS: The authors conducted a narrative literature review of published clinical guidelines, systematic reviews, and individual studies that addressed bronchitis with COPD exacerbations, CAP, UTIs, and cellulitis. This article is based on the best available evidence but was not a formal systematic review. Guidance was prioritized to the highest available level of synthesized evidence. Clinicians should limit antibiotic treatment duration to 5 days when managing patients with COPD exacerbations and acute uncomplicated bronchitis who have clinical signs of a bacterial infection (presence of increased sputum purulence in addition to increased dyspnea, and/or increased sputum volume). Clinicians should prescribe antibiotics for community-acquired pneumonia for a minimum of 5 days. Extension of therapy after 5 days of antibiotics should be guided by validated measures of clinical stability, which include resolution of vital sign abnormalities, ability to eat, and normal mentation. In women with uncomplicated bacterial cystitis, clinicians should prescribe short-course antibiotics with either nitrofurantoin for 5 days, trimethoprim-sulfamethoxazole (TMP-SMZ) for 3 days, or fosfomycin as a single dose. In men and women with uncomplicated pyelonephritis, clinicians should prescribe short-course therapy either with fluoroquinolones (5 to 7 days) or TMP-SMZ (14 days) based on antibiotic susceptibility. In patients with nonpurulent cellulitis, clinicians should use a 5- to 6-day course of antibiotics active against streptococci, particularly for patients able to self-monitor and who have close follow-up with primary care.
DESCRIPTION: Antimicrobial overuse is a major health care issue that contributes to antibiotic resistance. Such overuse includes unnecessarily long durations of antibiotic therapy in patients with common bacterial infections, such as acute bronchitis with chronic obstructive pulmonary disease (COPD) exacerbation, community-acquired pneumonia (CAP), urinary tract infections (UTIs), and cellulitis. This article describes best practices for prescribing appropriate and short-duration antibiotic therapy for patients presenting with these infections. METHODS: The authors conducted a narrative literature review of published clinical guidelines, systematic reviews, and individual studies that addressed bronchitis with COPD exacerbations, CAP, UTIs, and cellulitis. This article is based on the best available evidence but was not a formal systematic review. Guidance was prioritized to the highest available level of synthesized evidence. Clinicians should limit antibiotic treatment duration to 5 days when managing patients with COPD exacerbations and acute uncomplicated bronchitis who have clinical signs of a bacterial infection (presence of increased sputum purulence in addition to increased dyspnea, and/or increased sputum volume). Clinicians should prescribe antibiotics for community-acquired pneumonia for a minimum of 5 days. Extension of therapy after 5 days of antibiotics should be guided by validated measures of clinical stability, which include resolution of vital sign abnormalities, ability to eat, and normal mentation. In women with uncomplicated bacterial cystitis, clinicians should prescribe short-course antibiotics with either nitrofurantoin for 5 days, trimethoprim-sulfamethoxazole (TMP-SMZ) for 3 days, or fosfomycin as a single dose. In men and women with uncomplicated pyelonephritis, clinicians should prescribe short-course therapy either with fluoroquinolones (5 to 7 days) or TMP-SMZ (14 days) based on antibiotic susceptibility. In patients with nonpurulent cellulitis, clinicians should use a 5- to 6-day course of antibiotics active against streptococci, particularly for patients able to self-monitor and who have close follow-up with primary care.
Authors: Magdalene M Assimon; Patrick H Pun; Lily Chin-Hua Wang; Sana M Al-Khatib; M Alan Brookhart; David J Weber; Wolfgang C Winkelmayer; Jennifer E Flythe Journal: JAMA Cardiol Date: 2022-01-01 Impact factor: 30.154
Authors: Mark S Butler; Valeria Gigante; Hatim Sati; Sarah Paulin; Laila Al-Sulaiman; John H Rex; Prabhavathi Fernandes; Cesar A Arias; Mical Paul; Guy E Thwaites; Lloyd Czaplewski; Richard A Alm; Christian Lienhardt; Melvin Spigelman; Lynn L Silver; Norio Ohmagari; Roman Kozlov; Stephan Harbarth; Peter Beyer Journal: Antimicrob Agents Chemother Date: 2022-01-10 Impact factor: 5.191
Authors: Debra A Goff; Julie E Mangino; Elizabeth Trolli; Richard Scheetz; Douglas Goff Journal: Open Forum Infect Dis Date: 2022-07-25 Impact factor: 4.423
Authors: Robin M E Janssen; Anke J M Oerlemans; Johannes G Van Der Hoeven; Jaap Ten Oever; Jeroen A Schouten; Marlies E J L Hulscher Journal: J Antimicrob Chemother Date: 2022-07-28 Impact factor: 5.758
Authors: Alpesh N Amin; E Patchen Dellinger; Glenn Harnett; Bryan D Kraft; Kerry L LaPlante; Frank LoVecchio; James A McKinnell; Glenn Tillotson; Salisia Valentine Journal: Front Med (Lausanne) Date: 2022-07-27
Authors: R Cantón; J Barberán; M Linares; J M Molero; J M Rodríguez-González-Moro; M Salavert; J González Del Castillo Journal: Rev Esp Quimioter Date: 2022-01-19 Impact factor: 1.553